Atossa Therapeutics Inc
ATOS0.829USD
+0.006+0.73%
交易中 （美东）报价延迟15分钟
107.08M总市值
亏损市盈率 TTM
关于 Atossa Therapeutics Inc 公司
Atossa Therapeutics, Inc. 是一家临床阶段的生物制药公司。该公司致力于开发肿瘤学领域尚未满足的重大医疗需求领域的药物，重点是使用 (Z)-endoxifen 预防和治疗乳腺癌。该公司正在开发的主要候选药物是口服 (Z)-endoxifen，用于预防和治疗乳腺癌。(Z)-endoxifen 是一种强效的选择性雌激素受体调节剂，可抑制雌激素受体并导致雌激素受体降解。除了其强效的抗雌激素作用外，(Z)-endoxifen 还被证明可以在临床可达到的血液浓度下靶向已知的致癌蛋白 PKCB1。该公司正在开发一种口服的 (Z)-endoxifen 形式，用于治疗乳腺癌和降低乳腺密度。该公司已完成其专有的 (Z)-endoxifen（包括口服和外用制剂）的四项 I 期临床研究和两项 II 期临床研究。
公司简介
公司代码ATOS
公司名称Atossa Therapeutics Inc
上市日期Nov 08, 2012
CEODr. Steven C. (Steve) Quay, M.D., Ph.D.
员工数量13
证券类型Ordinary Share
年结日Nov 08
公司地址10202 5Th Avenue Ne
城市SEATTLE
上市交易所NASDAQ Capital Market Consolidated
国家United States of America
邮编98125
电话12065880256
网址https://atossatherapeutics.com/
公司代码ATOS
上市日期Nov 08, 2012
CEODr. Steven C. (Steve) Quay, M.D., Ph.D.
公司高管
名称
名称/职务
职务
持股
持股变动
Dr. Steven C. (Steve) Quay, M.D., Ph.D.
Dr. Steven C. (Steve) Quay, M.D., Ph.D.
Chairman of the Board, President, Chief Executive Officer
Chairman of the Board, President, Chief Executive Officer
36.15K
+45.11%
Dr. Shu-Chih Chen, Ph.D.
Dr. Shu-Chih Chen, Ph.D.
Director
Director
22.25K
--
Dr. Stephen J. Galli, M.D.
Dr. Stephen J. Galli, M.D.
Independent Director
Independent Director
99.00
--
Dr. Tessa Cigler, M.D.
Dr. Tessa Cigler, M.D.
Independent Director
Independent Director
--
--
Mr. Jonathan F. Finn
Mr. Jonathan F. Finn
Independent Director
Independent Director
--
--
Mr. H. Lawrence Remmel, Esq., J.D.
Mr. H. Lawrence Remmel, Esq., J.D.
Lead Independent Director
Lead Independent Director
--
--
Mr. Richard I. Steinhart
Mr. Richard I. Steinhart
Independent Director
Independent Director
--
--
Ms. Heather Rees, CPA
Ms. Heather Rees, CPA
Chief Financial Officer
Chief Financial Officer
--
--
Mr. Michael Parks
Mr. Michael Parks
Vice President, Investor and Public Relations
Vice President, Investor and Public Relations
--
--
名称
名称/职务
职务
持股
持股变动
Dr. Steven C. (Steve) Quay, M.D., Ph.D.
Dr. Steven C. (Steve) Quay, M.D., Ph.D.
Chairman of the Board, President, Chief Executive Officer
Chairman of the Board, President, Chief Executive Officer
36.15K
+45.11%
Dr. Shu-Chih Chen, Ph.D.
Dr. Shu-Chih Chen, Ph.D.
Director
Director
22.25K
--
Dr. Stephen J. Galli, M.D.
Dr. Stephen J. Galli, M.D.
Independent Director
Independent Director
99.00
--
Dr. Tessa Cigler, M.D.
Dr. Tessa Cigler, M.D.
Independent Director
Independent Director
--
--
Mr. Jonathan F. Finn
Mr. Jonathan F. Finn
Independent Director
Independent Director
--
--
Mr. H. Lawrence Remmel, Esq., J.D.
Mr. H. Lawrence Remmel, Esq., J.D.
Lead Independent Director
Lead Independent Director
--
--
收入明细
暂无数据
暂无数据
业务
地区
暂无数据
股东统计
更新时间: 8月2日 周六
更新时间: 8月2日 周六
持股股东
股东类型
持股股东
持股股东
占比
BlackRock Institutional Trust Company, N.A.
6.70%
The Vanguard Group, Inc.
4.52%
Heights Capital Management, Inc.
4.38%
Geode Capital Management, L.L.C.
2.20%
Columbia Threadneedle Investments (US)
2.00%
Other
80.19%
持股股东
持股股东
占比
BlackRock Institutional Trust Company, N.A.
6.70%
The Vanguard Group, Inc.
4.52%
Heights Capital Management, Inc.
4.38%
Geode Capital Management, L.L.C.
2.20%
Columbia Threadneedle Investments (US)
2.00%
Other
80.19%
股东类型
持股股东
占比
Investment Advisor
17.75%
Investment Advisor/Hedge Fund
5.93%
Hedge Fund
1.60%
Research Firm
0.63%
Bank and Trust
0.11%
Individual Investor
0.07%
Pension Fund
0.02%
Other
73.89%
机构持股
更新时间: 7月1日 周二
更新时间: 7月1日 周二
报告期
机构数
持股数
持股占比
持股变动
2025Q2
165
36.31M
28.11%
-5.30M
2025Q1
171
34.47M
26.69%
-7.71M
2024Q4
167
36.07M
28.67%
-3.59M
2024Q3
170
35.56M
28.29%
+4.15M
2024Q2
166
34.42M
27.39%
+12.85M
2024Q1
166
27.40M
21.83%
+6.49M
2023Q4
166
16.33M
13.03%
-5.47M
2023Q3
184
24.37M
19.38%
-1.84M
2023Q2
197
24.20M
19.13%
-3.27M
2023Q1
206
24.64M
19.46%
-4.55M
查看更多
股东持股明细
名称
持股数
占比
持股变动
变动比例
公告日期
BlackRock Institutional Trust Company, N.A.
8.66M
6.7%
-132.60K
-1.51%
Mar 31, 2025
The Vanguard Group, Inc.
6.59M
5.1%
-33.06K
-0.50%
Mar 31, 2025
Heights Capital Management, Inc.
5.66M
4.38%
-2.10M
-27.05%
Dec 31, 2024
Geode Capital Management, L.L.C.
2.85M
2.2%
+31.61K
+1.12%
Mar 31, 2025
Renaissance Technologies LLC
1.86M
1.44%
+297.47K
+19.10%
Mar 31, 2025
State Street Global Advisors (US)
1.73M
1.34%
-28.28K
-1.61%
Mar 31, 2025
Northern Trust Investments, Inc.
953.88K
0.74%
-71.25K
-6.95%
Mar 31, 2025
BlackRock Financial Management, Inc.
581.43K
0.45%
-2.34K
-0.40%
Mar 31, 2025
Squarepoint Capital LLP
479.00K
0.37%
+479.00K
--
Mar 31, 2025
查看更多
持股ETF
更新时间: 8月2日 周六
更新时间: 8月2日 周六
机构名称
占比
ProShares Hedge Replication ETF
0%
iShares Micro-Cap ETF
0%
iShares Russell 2000 Growth ETF
0%
Proshares Ultra Russell 2000
0%
ProShares UltraPro Russell2000
0%
iShares Russell 2000 Value ETF
0%
Global X Russell 2000 ETF
0%
iShares Russell 2000 ETF
0%
ProShares Hedge Replication ETF
占比0%
iShares Micro-Cap ETF
占比0%
iShares Russell 2000 Growth ETF
占比0%
Proshares Ultra Russell 2000
占比0%
ProShares UltraPro Russell2000
占比0%
iShares Russell 2000 Value ETF
占比0%
Global X Russell 2000 ETF
占比0%
iShares Russell 2000 ETF
占比0%
分红派息
近5年累计派现
0.00
美元
公告日期
分红计划
股权登记日
现金发放日
除权除息日
暂无数据
拆合股
公告日期
类型
比率
暂无数据
公告日期
类型
比率
暂无数据
